10x Genomics
341 hedge funds and large institutions have $15.2B invested in 10x Genomics in 2021 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 158 increasing their positions, 75 reducing their positions, and 46 closing their positions.
219% more call options, than puts
Call options by funds: $92.3M | Put options by funds: $29M
111% more repeat investments, than reductions
Existing positions increased: 158 | Existing positions reduced: 75
46% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 46
19% more capital invested
Capital invested by funds: $12.8B → $15.2B (+$2.46B)
7.16% more ownership
Funds ownership: 81.97% → 89.13% (+7.2%)
5% more funds holding
Funds holding: 324 → 341 (+17)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$658M |
| 2 |
BlackRock
New York
|
+$406M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$144M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$99.8M |
| 5 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$99.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$334M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$90.5M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$71.3M |
| 4 |
MCAV
Meritech Capital Associates V
Palo Alto,
California
|
-$59.6M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$58.1M |
TXG Hedge Fund Activity: Q2 2021 in Review
341 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q2 2021, worth a combined $15.2B — up 19% from $12.8B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new TXG positions and 46 closed out — a net gain of 21 holders — while 158 added to existing stakes and 75 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $658M. The largest seller was Fidelity Investments, cutting an estimated $334M.
- 341 institutional investors held 10x Genomics (TXG) as of Q2 2021, up from 324 in Q1 2021.
- Funds reported $15.2B of 10x Genomics stock for Q2 2021, up 19% quarter-over-quarter.
- 67 funds opened new 10x Genomics positions in Q2 2021 and 46 closed out, a net change of +21 holders.
- The largest 10x Genomics buyer in Q2 2021 was Baillie Gifford & Co, an estimated $658M added.
- The largest 10x Genomics seller in Q2 2021 was Fidelity Investments, an estimated $334M sold.
Based on aggregated 13F filings for Q2 2021.